Meatly secures £10.4m series A to build pilot facility for cultivated meat
This article covers Meatly, a biotech startup, and its announcement on 7 May 2026 that it raised £10.4m in a series A funding round to build a pilot facility. The development supports Meatly’s move from lab-scale development towards production readiness for cultivated meat and affects investors, regulators and other stakeholders in the alternative-protein sector.
Meatly, a biotech startup, has raised £10.4m in a series A funding round to build a pilot facility, the company announced on 7 May 2026. The investment marks a move from lab-scale development toward a production-ready footprint for its cultivated meat efforts, a development that matters because pilot facilities are a costly but critical step on the path to commercial supply.
Why it matters
Pilot facilities are where many technical unknowns get resolved: reproducible cell lines, consistent media formulations, upstream and downstream processing, and quality control protocols. For cultivated meat ventures, the jump from bench to pilot is also where costs, regulatory engagement and supply-chain realities start to crystallise. A successful pilot can reduce technical risk and make follow-on funding and commercial partnerships more attainable.
Inside the product
The announcement says Meatly will use the funding to build a pilot facility. While the company did not provide detailed technical specifications in the release, pilot sites typically focus on process optimisation, scale-up of bioprocesses, ingredient sourcing and safety testing. For investors and potential commercial partners, the immediate outputs to watch for will be batch consistency, yield metrics and any early regulatory or safety data the company can share.
Who are the investors?
Meatly disclosed the size of the round but did not name lead investors or participating backers in the public announcement. The company has reported raising £10.4m but has not published a breakdown of investor types, strategic partners or anchor commitments at this time.
If you're researching potential backers in this space:
- Explore our list of foodtech venture capital firms in the UK
- Browse our directory of foodtech angel investors in the UK
Founder perspective
The press release did not include comments from founders or named executives. That absence leaves some open questions around the team leading the pilot build and the timetable for commissioning and validation. For founders of biotech startups, recruiting experienced operations and regulatory hires is typically a near-term priority after closing capital to run a pilot facility efficiently.
The bigger picture
The deal sits within sustained investor interest in alternative proteins and cultivated meat across Europe and internationally. Moving to a pilot stage aligns with a broader pattern among biotech startups trying to de-risk production ahead of larger scale funding or commercial partnerships. Regulatory frameworks in the UK and EU for cultivated meat continue to evolve, and progress at pilot scale will be important for engaging regulators and potential retail or foodservice partners.
This funding news is another signal that capital is still flowing into production-readiness for cultivated meat in the UK and Europe, where a successful pilot can be the difference between remaining a lab project and becoming a commercially viable product.
Click here for a full list of 7,589+ startup investors in the UK